Company news
Simcere Pharmaceutical Group Limited news in 2026
Simcere Pharmaceutical Group Limited's news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 4, 2026
Next Day Disclosure Return
November 3, 2026
Voluntary announcement - entering into an exclusive promotion services agreement with lynk pharmaceuticals in respect of dermatological indications of zemprocitinib
November 2, 2026
Next Day Disclosure Return
October 27, 2026
Next Day Disclosure Return
October 26, 2026
Next Day Disclosure Return
October 23, 2026
Next Day Disclosure Return
October 22, 2026
Next Day Disclosure Return
October 13, 2026
Next Day Disclosure Return
October 9, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 5, 2026
Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
September 24, 2026
Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
September 24, 2026
2026 Interim report
September 24, 2026
(Revised) Next Day Disclosure Return
September 14, 2026
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
September 1, 2026
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
June 12, 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026